Re: Context on Sales Potential for an oral anti-viral & anti-inflammation combo
posted on
Apr 14, 2021 06:44PM
Tada, I'm willing to bet the masses already know what replacing stroke with HF will likely do for BoM2. I think the masses are waiting to see where the money is coming from and how expensive it will be for existing shareholders. FYI, FINRA is an American watchdog so would have zero to do with the Shieks deal. If the hold up is truly regulatory I imagine it is at the Saudi end (we were told it was to do with a foreign govts review process) and probably has something to do with the Saudi/Canadian spats over the last few years.